Hims & Hers falls after FDA ends shortage of Lilly weight loss drug

The Food and Drug Administration re-evaluated its determination from October 2 on the status of the tirzepatide shortage. Eli Lilly’s (LLY) weight loss drug Zepbound is the branded name for tirzepatide. The FDA issued a new decision determining the tirzepatide injection shortage is resolved. FDA’s determination is based on its analysis of all the information before the agency. Shares of Hims & Hers (HIM) are down 7%, or $2.05, to $26.46 following the news. Hims & Hers sells a compounded version of the weight loss drug.